• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射甲基强的松龙脉冲治疗与中度至重度格雷夫斯眼病患者的小梁骨评分评估中的骨微结构丢失相关:一项初步研究。

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.

机构信息

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

出版信息

Front Endocrinol (Lausanne). 2022 Jul 14;13:893600. doi: 10.3389/fendo.2022.893600. eCollection 2022.

DOI:10.3389/fendo.2022.893600
PMID:35909547
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9331277/
Abstract

BACKGROUND

Therapy with intravenous glucocorticoids (GCs) is associated with various side effects, however, the impact on bone remains elusive. Trabecular bone score (TBS) is a diagnostic tool providing information on bone microarchitecture based on images obtained from dual-energy X-ray absorptiometry. We investigated the influence of the intravenous methylprednisolone (IVMP) pulse administration on TBS in patients with moderate-to-severe Graves' orbitopathy (GO).

METHODS

Fifteen patients with GO were treated with 12 IVMP pulses (6x0.5g, 6x0.25 g on a weekly schedule). They received supplementation with 2000 IU of vitamin D and 1.0 g of calcium throughout the study period. TBS was assessed at baseline and after last IVMP pulse. To determine the difference between values at baseline and after treatment the least significant change (LSC) methodology was used. We compared pre- and posttreatment mean TBS values.

RESULTS

We found a significant decrease of TBS in 5 out of 15 (33%) patients. Mean TBS value decreased becoming 2.4% lower than at baseline (p<0.05).

CONCLUSIONS

IVMP pulse therapy exerts negative effect on bone microarchitecture in TBS assessment. The analysis of the clinical risk factors for osteoporosis and the evaluation of bone mineral density and TBS should be considered before initiating IVMP therapy.

摘要

背景

静脉注射糖皮质激素(GCs)治疗与各种副作用相关,但对骨骼的影响仍不清楚。骨小梁评分(TBS)是一种诊断工具,可根据双能 X 射线吸收法获得的图像提供有关骨微观结构的信息。我们研究了静脉注射甲泼尼龙(IVMP)脉冲给药对中度至重度格雷夫斯眼病(GO)患者 TBS 的影响。

方法

15 名 GO 患者接受了 12 次 IVMP 脉冲治疗(每周 6x0.5g,6x0.25g)。在整个研究期间,他们接受了 2000IU 维生素 D 和 1.0g 钙的补充。在基线和最后一次 IVMP 脉冲后评估 TBS。为了确定治疗前后值之间的差异,使用了最小有意义变化(LSC)方法。我们比较了治疗前后的平均 TBS 值。

结果

我们发现 15 名患者中有 5 名(33%)TBS 显著下降。TBS 值平均下降 2.4%,低于基线(p<0.05)。

结论

IVMP 脉冲治疗对 TBS 评估中的骨微观结构产生负面影响。在开始 IVMP 治疗之前,应考虑分析骨质疏松的临床危险因素以及评估骨矿物质密度和 TBS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d72/9331277/2b18a36dc649/fendo-13-893600-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d72/9331277/d01fb1a51f80/fendo-13-893600-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d72/9331277/2b18a36dc649/fendo-13-893600-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d72/9331277/d01fb1a51f80/fendo-13-893600-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d72/9331277/2b18a36dc649/fendo-13-893600-g002.jpg

相似文献

1
Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study.静脉注射甲基强的松龙脉冲治疗与中度至重度格雷夫斯眼病患者的小梁骨评分评估中的骨微结构丢失相关:一项初步研究。
Front Endocrinol (Lausanne). 2022 Jul 14;13:893600. doi: 10.3389/fendo.2022.893600. eCollection 2022.
2
Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.静脉注射甲基强的松龙脉冲治疗中重度格雷夫斯眼病与骨密度丢失无关。
Endocrine. 2019 May;64(2):308-315. doi: 10.1007/s12020-018-1823-x. Epub 2018 Dec 1.
3
Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.静脉注射甲基强的松龙治疗中重度活动型格雷夫斯眼病后导致的糖皮质激素诱导的肾上腺功能不全:小剂量促皮质素试验评估。
J Endocrinol Invest. 2024 Aug;47(8):1987-1994. doi: 10.1007/s40618-024-02304-7. Epub 2024 Feb 4.
4
Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.静脉注射甲泼尼龙脉冲治疗重度格雷夫斯眼病的血压特征和 N 端脑利钠肽前体动态变化。
Int J Mol Sci. 2018 Sep 26;19(10):2918. doi: 10.3390/ijms19102918.
5
Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.格雷夫斯眼眶病患者静脉注射甲泼尼龙冲击治疗期间骨形成和骨吸收的减少
J Clin Med. 2022 Aug 26;11(17):5005. doi: 10.3390/jcm11175005.
6
High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.大剂量静脉注射甲泼尼龙冲击疗法会导致血清钙和磷水平短暂升高。
Pol Merkur Lekarski. 2019 Sep 25;47(279):91-94.
7
Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.Graves 眼病患者短期大剂量糖皮质激素治疗后的骨转换标志物、BMD 和 TBS:一项小型前瞻性初步研究。
J Endocrinol Invest. 2019 Jul;42(7):859-865. doi: 10.1007/s40618-018-0992-z. Epub 2018 Dec 5.
8
High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.大剂量静脉注射甲基强的松龙治疗格雷夫斯眼病与因子 VIII 活性增加有关。
J Endocrinol Invest. 2019 Feb;42(2):217-225. doi: 10.1007/s40618-018-0907-z. Epub 2018 Jun 9.
9
Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves' orbitopathy.在 Graves 眼病的治疗中,每周给予高剂量甲基泼尼松龙治疗 12 周可使骨转换减少,骨结构改善。
Endocrine. 2023 Dec;82(3):664-672. doi: 10.1007/s12020-023-03494-5. Epub 2023 Sep 7.
10
Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].考虑到欧洲 Graves 眼病专家组(EUGOGO)的建议,优化中重度和活动型甲状腺眼病的治疗[Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)]。
Endokrynol Pol. 2022;73(4):756-777. doi: 10.5603/EP.a2022.0040.

引用本文的文献

1
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.乌克兰糖皮质激素诱导性骨质疏松症防治指南。
Arch Osteoporos. 2025 Feb 24;20(1):31. doi: 10.1007/s11657-025-01512-9.
2
Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies.甲状腺相关性眼病与铁死亡:病理机制及治疗策略综述
Front Immunol. 2024 Dec 6;15:1475923. doi: 10.3389/fimmu.2024.1475923. eCollection 2024.
3
Bone density and microarchitecture in Graves' disease: evaluating treatment and vitamin D supplementation.

本文引用的文献

1
Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids.小梁骨评分(TBS)在接受糖皮质激素治疗的风湿病患者骨折风险评估中的临床应用
Horm Metab Res. 2021 Aug;53(8):499-503. doi: 10.1055/a-1528-7261. Epub 2021 Aug 12.
2
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.2021 年欧洲 Graves 眼病专家组(EUGOGO)Graves 眼病医学管理临床实践指南。
Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479.
3
Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.
格雷夫斯病中的骨密度与微结构:评估治疗与维生素D补充情况
Osteoporos Int. 2025 Feb;36(2):345-346. doi: 10.1007/s00198-024-07290-3. Epub 2024 Nov 1.
4
Bone microarchitecture and bone mineral density in Graves' disease.格雷夫斯病中的骨微结构和骨矿物质密度
Osteoporos Sarcopenia. 2023 Jun;9(2):70-75. doi: 10.1016/j.afos.2023.05.001. Epub 2023 Jun 1.
5
Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging.有关在骨质疏松症管理中使用小梁骨评分 (TBS) 的临床应用的最新情况:欧洲临床和经济骨质疏松症、骨关节炎和肌肉骨骼疾病学会 (ESCEO) 与国际骨质疏松基金会 (IOF) 在世界卫生组织协作中心的主持下举办的专家组会议的结果,该中心负责骨骼肌肉健康和老龄化的流行病学。
Osteoporos Int. 2023 Sep;34(9):1501-1529. doi: 10.1007/s00198-023-06817-4. Epub 2023 Jul 1.
糖皮质激素撤药——临床实践中肾上腺皮质功能不全的诊断时机与方法概述
Diagnostics (Basel). 2021 Apr 20;11(4):728. doi: 10.3390/diagnostics11040728.
4
Treatment with Intravenous Methylprednisolone in Patients with Graves' Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate.静脉注射甲泼尼龙治疗格雷夫斯眼眶病患者对肾上腺功能有显著影响:血清、唾液皮质醇及血清硫酸脱氢表雄酮的评估
J Clin Med. 2020 Oct 9;9(10):3233. doi: 10.3390/jcm9103233.
5
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses.糖皮质激素性骨质疏松症中的椎体骨折风险:性腺功能减退和糖皮质激素冲击疗法的作用
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001355.
6
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.骨小梁评分可改善糖皮质激素性骨质疏松症的骨折风险评估。
Rheumatology (Oxford). 2020 Jul 1;59(7):1574-1580. doi: 10.1093/rheumatology/kez464.
7
Trabecular bone score of postmenopausal women is positively correlated with bone mineral density and negatively correlated with age and body mass index.绝经后妇女的小梁骨评分与骨密度呈正相关,与年龄和体重指数呈负相关。
Menopause. 2019 Oct;26(10):1166-1170. doi: 10.1097/GME.0000000000001375.
8
Changes in bone mineral density and trabecular bone score in Graves' disease patients after anti-thyroid therapy.抗甲状腺治疗后Graves病患者骨密度和骨小梁评分的变化
Osteoporos Sarcopenia. 2016 Sep;2(3):175-179. doi: 10.1016/j.afos.2016.05.004. Epub 2016 Jun 21.
9
Bone turnover markers, BMD and TBS after short-term, high-dose glucocorticoid therapy in patients with Graves' orbitopathy: a small prospective pilot study.Graves 眼病患者短期大剂量糖皮质激素治疗后的骨转换标志物、BMD 和 TBS:一项小型前瞻性初步研究。
J Endocrinol Invest. 2019 Jul;42(7):859-865. doi: 10.1007/s40618-018-0992-z. Epub 2018 Dec 5.
10
Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.静脉注射甲基强的松龙脉冲治疗中重度格雷夫斯眼病与骨密度丢失无关。
Endocrine. 2019 May;64(2):308-315. doi: 10.1007/s12020-018-1823-x. Epub 2018 Dec 1.